Relay Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RLAY | ERAS | 2256.HK | IDYA | SNDX | TNGX | |
|---|---|---|---|---|---|---|
| Market cap | 3.95B | 5.21B | 5.03B | 3.12B | 940.80M | 3.91B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -11.0 | -23.9 | -24.1 | -7.9 | -14.4 | -13.8 |
| Price/book | 5.5 | 12.9 | 2.0 | 2.9 | -54.7 | 3.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +166.26% | +565.45% | −54.94% | +5.63% | −5.36% | +208.52% |
| Today | +3.38% | +1.84% | +6.85% | +3.29% | −26.87% | +0.04% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All RLAY news ›Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
November 04, 2026 16:05 ET | Source: Relay Therapeutics, Inc. Relay Therapeutics, Inc. Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027 Updated data from ongoing Phase 1/2 ReInspire trial of…
Praxis Precision Medicines (NASDAQ:PRAX) and Relay Therapeutics (NASDAQ:RLAY) Financial Review
Posted by Defense World Staff on Oct 27th, 2026 Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) and Relay Therapeutics (NASDAQ:RLAY – Get Free Report) are both mid-cap healthcare companies, but which is the better stock? We will…
Relay: The Recent Market Excitement Ignores The Reality Of Clinical Risks And Patent Cliffs
Relay is rated Hold despite a 175% rally, given overvaluation relative to a risk-adjusted fair value of $13.53 per share. Read more on RLAY stock here. - Relay Therapeutics is rated Hold despite a 175% rally, given overvaluation relative…
Relay Therapeutics: Patel proposes $1.81M share sale
Relay Therapeutics (RLAY) is a Nasdaq-listed clinical-stage precision medicine company using its Dynamo platform to develop small molecule therapies for cancer and genetic disease. Relay Therapeutics: Patel proposes $1.81M share sale The…
Relay Therapeutics CEO sells 48,199 shares
CEO sells 48,199 shares under a trading plan at Relay Therapeutics (RLAY). Stock Titan - [Form 4] Relay Therapeutics, Inc. Insider Trading Activity Relay Therapeutics CEO sells 48,199 shares The sale was made under a Rule 10b5-1 plan…
Relay Therapeutics CFO sells 17,511 shares
Relay Therapeutics (RLAY) is a Nasdaq-listed clinical-stage precision medicine company using its Dynamo platform to develop small molecule therapies for cancer and genetic disease. - [Form 4] Relay Therapeutics, Inc. Insider Trading…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net4
- defenseworld.net1
- globenewswire.com1
- seekingalpha.com1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.